BLAINJECTIONINJECTABLE
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Clinical Trials (3)
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Started Nov 2025
This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry
Started Nov 2022
255 enrolled
Arthritis, Rheumatoid
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
Started Oct 2016
1,431 enrolled
Crohn DiseaseUlcerative ColitisRheumatoid Arthritis+2 more